A Phase 2 Study of VS-6766 and Defactinib in People with Advanced Mesonephric Gynecologic Cancer


Full Title

Single Arm Phase II Study of Avutometinib (VS-6766) and Defactinib in Advanced or Recurrent Mesonephric Gynecologic Cancer


Mesonephric cancer is a rare gynecologic cancer. The purpose of this study is to assess the safety and effectiveness of giving VS-6766 and defactinib together in people with advanced or recurrent mesonephric gynecologic cancers.

VS-6766 and defactinib inhibit enzymes called kinases found on the surface of cancer cells, and cancer cells need these enzymes to survive and grow. When these enzymes are blocked, a cancer may stop growing or grow more slowly, and the cancer cells may shrink. VS-6766 and defactinib are both taken orally (by mouth).

Who Can Join

To be eligible for this study, patients must meet several requirements, including:

  • Participants must have mesonephric gynecologic cancer that has metastasized or came back after prior therapy.
  • At least 4 weeks must pass since the completion of previous anti-cancer treatments and receipt of the study therapy.
  • This study is for women age 18 and older.


For more information and to ask about eligibility for this study, please contact the office of Dr. Rachel Grisham at 646-888-4653.




Phase II (phase 2)

Disease Status

Relapsed or Refractory



ClinicalTrials.gov ID